Reports available on Market Reports World incorporate a comprehensive research statistics of all aspects of the market that offer you a thorough business intelligence. Gaining an in-depth predicative and competitive analysis of the market aids your business in dominating the market and that is what we aspire towards. Market Reports World provide you various industry-centric reports that aid your business in augmenting its growth. The reports we sell are integrated with market analysis data of the key players, leading market segments and latest market trends across the globe.

Description
According to the data released by China’s National Health Commission in Oct. 2018, the incidence of childhood leukemia in Chinese children under 15 is about 4/100,000 to 5/100,000, and the number of childhood leukemia patients under 18 old increases by about 15,000 every year. Childhood leukemia is the second leading cause of death among children under 15 in China. It mainly includes acute leukemia (about 5%), chronic leukemia (3% to 5%) and myelodysplastic syndrome. Acute lymphoblastic leukemia accounts for 70% of childhood leukemia and the cure rate of such leukemia is close to 90%. The other kind of childhood leukemia is acute non-lymphocytic leukemia. The cure rate of acute promyelocytic leukemia in this class has exceeded 90%.
Pegaspargase is an asparaginase preparation that binds Escherichia coli-derived L-asparaginase with polyethylene glycol and lipid bilayer. Compared with L-asparaginase, Pegaspargase retains the bioactivity of asparaginase. Besides, it maintains liposome morphology before accessing tumor tissue, which avoids decomposition by proteinases and extends the half-life of Pegaspargase to (7±2) days. It is a long-acting asparaginase preparation. One-time use of Pegaspargase can replace multiple uses of L-asparaginase, which shortens the period of hospitalization. Pegaspargase is also featured by less immunogenicity and allergic reactions, especially immediate allergic reactions. In terms of other adverse reactions, Pegaspargase is similar to L-asparaginase.
According to Report, branded Pegaspargase (trade name: Oncaspar) was developed by Enzon Pharmaceuticals, Inc. In 1994, it was approved by the FDA to be applied to those who have acute lymphoblastic leukemia and are allergic to L-asparaginase. In 2000, it was approved by the FDA to be used in the first-line treatment of newly diagnosed leukemia patients. For many reasons, Oncaspar has not been approved to be sold in China. In 2009, the generic Pegaspargase injection developed by Jiangsu Hengrui Medicine Co., Ltd. was approved by the CFDA to be sold in China. By Aug. 2019, only Jiangsu Hengrui Medicine Co., Ltd. has been approved to sell Pegaspargase in China. Other Chinese pharmaceutical companies such as Beijing SL Pharmaceutical Co., Ltd. are also developing generic Pegaspargase. Their Pegaspargase products are expected to be launched in China by 2023.
In China, Pegaspargase is used to treat acute lymphoblastic leukemia. Those who are allergic to natural L-asparaginase can try Pegaspargase. In general, Pegaspargase is used together with other chemotherapy drugs such as vincristine (Oncovin), methotrexate, cytarabine, daunorubicin and pirarubicin. Only when the combined use is confirmed inapplicable will it be used alone. Pegaspargase has proved to have similar curative effect as natural L-asparaginase. It can be used to treat those who are seriously allergic to natural L-asparaginase as well as those who have non-Hodgkin’s lymphoma or acute myeloid leukemia.
According to Report, the sales value of Pegaspargase kept rising after the drug was launched in China. In 2017, it reached about CNY 74 million, representing a CAGR of 20.10% from 2013 to 2017. As environmental pollution and decoration pollution worsen, the number of leukemia patients in China will keep increasing. Therefore, the market size of Pegaspargase in China will continue to expand from 2019 to 2023. By then, in addition to Aiyang by Jiangsu Hengrui Medicine Co., Ltd., more Pegaspargase products will be approved to be put on the market.

Our Clients

The Global Animal Genetics Market is anticipated to extent USD 5.50 billion by 2021, growing at a CAGR of 8.4% from 2016 to 2021. Growth Factors in Animal Genetics Market such as Rising consumer demand for animal-derived protein Growing population and rapid urbanization across the globe Increased adoption of advanced ...

The Global Top 10 Medical Device Technologies Market is anticipated to extent USD 428,970.7 million by 2020, growing at a CAGR of 5.5% during the forecast period (2015 to 2020). The market is mainly driven by the rising prevalence of chronic diseases and related increase in disability-adjusted life years (DALYs), tech...

Imitrex Sales Market Production, Supply, Sales, and Demand Research Report is a systematically conducted exhaustive study of the Imitrex Sales market. The aim of the Imitrex Sales Industry report is to assist novice as well as seeded players in gaining astute business intelligence and make apt decisions based on it. D...

Implantable Cardioverter Defibrillator Market Production, Supply, Sales, and Demand Research Report is a systematically conducted exhaustive study of the Implantable Cardioverter Defibrillator market. The aim of the Implantable Cardioverter Defibrillator Industry report is to assist novice as well as seeded players in...